| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
19,915 |
18,458 |
$3.17M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
14,468 |
13,174 |
$2.95M |
| A0429 |
Ambulance service, basic life support, emergency transport (bls-emergency) |
7,297 |
5,602 |
$2.28M |
| A0427 |
Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) |
6,492 |
5,365 |
$2.21M |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
21,632 |
4,219 |
$1.39M |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
17,857 |
3,741 |
$1.34M |
| A0425 |
Ground mileage, per statute mile |
15,257 |
11,254 |
$926K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
27,401 |
21,240 |
$786K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,616 |
4,330 |
$539K |
| A0998 |
Ambulance response and treatment, no transport |
2,649 |
1,658 |
$528K |
| G0381 |
Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
6,700 |
6,356 |
$317K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
5,927 |
1,741 |
$308K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
8,437 |
7,638 |
$288K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,121 |
1,027 |
$231K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
234 |
207 |
$133K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,238 |
1,167 |
$73K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
135 |
126 |
$73K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
106 |
76 |
$71K |
| G0378 |
Hospital observation service, per hour |
407 |
330 |
$68K |
| 80053 |
Comprehensive metabolic panel |
15,443 |
13,903 |
$67K |
| 36415 |
Collection of venous blood by venipuncture |
23,131 |
20,089 |
$65K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
282 |
254 |
$61K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
3,864 |
3,444 |
$59K |
| 71045 |
Radiologic examination, chest; single view |
3,848 |
3,549 |
$54K |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
40 |
39 |
$54K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
348 |
333 |
$42K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
169 |
105 |
$34K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,569 |
2,144 |
$34K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
213 |
162 |
$32K |
| 73630 |
|
1,051 |
744 |
$30K |
| 93296 |
|
1,609 |
1,553 |
$26K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
329 |
289 |
$23K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
25,611 |
22,781 |
$22K |
| 71046 |
Radiologic examination, chest; 2 views |
988 |
900 |
$21K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,756 |
1,534 |
$21K |
| 70450 |
Computed tomography, head or brain; without contrast material |
314 |
281 |
$19K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
350 |
239 |
$19K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
6,443 |
5,836 |
$18K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
104 |
95 |
$16K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,004 |
786 |
$14K |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
89 |
79 |
$13K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
332 |
104 |
$12K |
| 97161 |
|
330 |
308 |
$12K |
| 95811 |
|
13 |
13 |
$12K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
151 |
144 |
$10K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
143 |
125 |
$9K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
102 |
45 |
$8K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
7,239 |
6,371 |
$8K |
| 76830 |
Ultrasound, transvaginal |
120 |
105 |
$7K |
| 88142 |
|
725 |
671 |
$7K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,667 |
3,908 |
$7K |
| 97035 |
|
334 |
125 |
$6K |
| 52000 |
|
13 |
12 |
$6K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
302 |
267 |
$6K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
566 |
543 |
$6K |
| 62323 |
|
28 |
25 |
$6K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
79 |
70 |
$6K |
| 95951 |
|
18 |
13 |
$5K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
37 |
35 |
$5K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
148 |
132 |
$5K |
| 93976 |
|
58 |
52 |
$5K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
146 |
131 |
$5K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
64 |
59 |
$4K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
70 |
61 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
178 |
170 |
$4K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
56 |
53 |
$3K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
35 |
34 |
$3K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
4,209 |
3,052 |
$3K |
| 11721 |
|
1,237 |
1,153 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
16 |
12 |
$3K |
| 84484 |
|
3,759 |
3,135 |
$3K |
| Q9965 |
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
782 |
706 |
$3K |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
5,048 |
3,269 |
$3K |
| J2704 |
Injection, propofol, 10 mg |
2,484 |
1,351 |
$3K |
| 97165 |
|
145 |
124 |
$3K |
| 73610 |
|
227 |
147 |
$3K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
29 |
27 |
$2K |
| 80061 |
Lipid panel |
378 |
355 |
$2K |
| 93922 |
|
68 |
67 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
350 |
332 |
$2K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,092 |
988 |
$2K |
| 73562 |
|
161 |
127 |
$2K |
| 83690 |
|
3,635 |
3,278 |
$2K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
68 |
26 |
$2K |
| 87631 |
|
32 |
32 |
$2K |
| 97162 |
|
65 |
55 |
$2K |
| 92558 |
|
146 |
120 |
$2K |
| 73110 |
|
95 |
58 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,831 |
3,369 |
$1K |
| 97116 |
|
142 |
40 |
$1K |
| 97166 |
|
42 |
40 |
$1K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
47 |
41 |
$1K |
| 81001 |
|
4,685 |
4,277 |
$1K |
| 94060 |
|
29 |
28 |
$1K |
| 88342 |
|
70 |
63 |
$1K |
| 76801 |
|
15 |
14 |
$1K |
| J3490 |
Unclassified drugs |
1,247 |
716 |
$1K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
32 |
28 |
$1K |
| 83735 |
|
2,123 |
1,886 |
$1K |
| 71250 |
|
44 |
42 |
$1K |
| 85027 |
|
476 |
425 |
$985.46 |
| 80069 |
|
104 |
95 |
$879.25 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
28 |
26 |
$873.96 |
| 84443 |
Thyroid stimulating hormone (TSH) |
504 |
455 |
$869.82 |
| 94618 |
|
15 |
15 |
$807.36 |
| 73030 |
|
84 |
73 |
$794.54 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
589 |
462 |
$794.18 |
| 93298 |
|
30 |
30 |
$704.53 |
| 73130 |
|
55 |
38 |
$671.36 |
| 86803 |
|
18 |
16 |
$604.05 |
| G0008 |
Administration of influenza virus vaccine |
58 |
55 |
$585.46 |
| 93299 |
|
95 |
95 |
$575.38 |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
14 |
12 |
$434.99 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
119 |
107 |
$434.79 |
| 80076 |
|
917 |
834 |
$409.22 |
| 76775 |
|
12 |
12 |
$400.05 |
| 76000 |
|
25 |
12 |
$387.24 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,848 |
1,035 |
$328.03 |
| 73140 |
|
20 |
14 |
$321.88 |
| 20610 |
|
36 |
30 |
$320.43 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
18 |
16 |
$315.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
12 |
12 |
$275.00 |
| 73590 |
|
22 |
12 |
$265.98 |
| 81025 |
|
858 |
773 |
$256.46 |
| 93971 |
|
14 |
13 |
$245.49 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,601 |
1,068 |
$239.55 |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
15 |
12 |
$237.28 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,351 |
1,031 |
$178.03 |
| 92134 |
|
114 |
109 |
$176.46 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
212 |
133 |
$163.48 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,768 |
1,305 |
$160.66 |
| 84145 |
|
139 |
125 |
$140.54 |
| 86140 |
|
196 |
156 |
$134.25 |
| J1644 |
Injection, heparin sodium, per 1000 units |
362 |
122 |
$125.57 |
| 20611 |
|
13 |
12 |
$116.48 |
| 83655 |
|
15 |
14 |
$107.24 |
| 83605 |
|
370 |
336 |
$102.97 |
| L3908 |
Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf |
14 |
12 |
$102.54 |
| 74019 |
|
70 |
67 |
$98.76 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
366 |
309 |
$95.37 |
| A9573 |
Injection, gadopiclenol, 1 ml |
17 |
13 |
$86.97 |
| 84703 |
|
144 |
132 |
$84.93 |
| 82565 |
|
100 |
79 |
$76.96 |
| 81003 |
|
535 |
500 |
$75.30 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
275 |
258 |
$62.75 |
| 85379 |
|
57 |
50 |
$62.44 |
| J7999 |
Compounded drug, not otherwise classified |
16 |
15 |
$56.57 |
| 51798 |
|
64 |
58 |
$50.40 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
527 |
480 |
$43.81 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
93 |
89 |
$32.31 |
| 85652 |
|
227 |
189 |
$30.22 |
| 84702 |
|
13 |
12 |
$30.10 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
39 |
39 |
$24.16 |
| 87210 |
|
33 |
24 |
$5.81 |
| J2060 |
Injection, lorazepam, 2 mg |
70 |
57 |
$0.70 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
95 |
85 |
$0.00 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
264 |
202 |
$0.00 |
| 87510 |
|
120 |
103 |
$0.00 |
| 96376 |
|
210 |
142 |
$0.00 |
| A9270 |
Non-covered item or service |
783 |
443 |
$0.00 |
| 94760 |
|
225 |
140 |
$0.00 |
| 87280 |
|
20 |
20 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
327 |
194 |
$0.00 |
| C1769 |
Guide wire |
393 |
232 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
146 |
106 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
201 |
126 |
$0.00 |
| 87480 |
|
120 |
103 |
$0.00 |
| 82962 |
|
189 |
163 |
$0.00 |
| 82728 |
|
17 |
15 |
$0.00 |
| 92567 |
|
423 |
359 |
$0.00 |
| 87040 |
|
89 |
75 |
$0.00 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
67 |
44 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
322 |
219 |
$0.00 |
| 87088 |
|
85 |
77 |
$0.00 |
| 83880 |
|
81 |
70 |
$0.00 |
| 96127 |
|
25 |
24 |
$0.00 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
54 |
40 |
$0.00 |
| 86901 |
|
12 |
12 |
$0.00 |
| 82550 |
|
36 |
28 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
17 |
14 |
$0.00 |
| 85730 |
|
48 |
39 |
$0.00 |
| 85018 |
|
94 |
71 |
$0.00 |
| 86850 |
|
12 |
12 |
$0.00 |
| 83615 |
|
16 |
12 |
$0.00 |
| 97535 |
Self-care/home management training, each 15 minutes |
171 |
74 |
$0.00 |
| 90686 |
|
14 |
13 |
$0.00 |
| 73502 |
|
17 |
15 |
$0.00 |
| 87077 |
|
29 |
26 |
$0.00 |
| A4217 |
Sterile water/saline, 500 ml |
13 |
12 |
$0.00 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
16 |
12 |
$0.00 |
| V5266 |
Battery for use in hearing device |
64 |
59 |
$0.00 |
| 85049 |
|
70 |
57 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
216 |
192 |
$0.00 |
| 74018 |
|
43 |
31 |
$0.00 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
457 |
356 |
$0.00 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
191 |
185 |
$0.00 |
| 94729 |
|
16 |
15 |
$0.00 |
| 87660 |
|
120 |
103 |
$0.00 |
| 85610 |
|
387 |
304 |
$0.00 |
| 87186 |
|
137 |
130 |
$0.00 |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
34 |
24 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
281 |
215 |
$0.00 |
| 84100 |
|
44 |
28 |
$0.00 |
| J7699 |
Noc drugs, inhalation solution administered through dme |
12 |
12 |
$0.00 |
| 86900 |
|
12 |
12 |
$0.00 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
128 |
77 |
$0.00 |
| 92557 |
|
32 |
28 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
13 |
12 |
$0.00 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
64 |
61 |
$0.00 |
| 99152 |
|
15 |
12 |
$0.00 |
| 84460 |
|
31 |
27 |
$0.00 |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
13 |
13 |
$0.00 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
15 |
12 |
$0.00 |
| 84439 |
|
13 |
13 |
$0.00 |
| 94726 |
|
15 |
14 |
$0.00 |